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A challenge in clinical genomics is to predict whether copy number variation (CNV) affecting a 
gene or multiple genes will manifest as disease. Increasing recognition of gene dosage effects in 
neurodevelopmental disorders prompted us to develop a computational approach based on critical-
exon (highly expressed in brain, highly conserved) examination for potential etiologic effects. Using 
a large CNV dataset, our updated analyses revealed significant (P < 1.64 × 10−15) enrichment of 
critical-exons within rare CNVs in cases compared to controls. Separately, we used a weighted gene co-
expression network analysis (WGCNA) to construct an unbiased protein module from prenatal and adult 
tissues and found it significantly enriched for critical exons in prenatal (P < 1.15 × 10−50, OR = 2.11) 
and adult (P < 6.03 × 10−18, OR = 1.55) tissues. WGCNA yielded 1,206 proteins for which we prioritized 
the corresponding genes as likely to have a role in neurodevelopmental disorders. We compared the 
gene lists obtained from critical-exon and WGCNA analysis and found 438 candidate genes associated 
with CNVs annotated as pathogenic, or as variants of uncertain significance (VOUS), from among 
10,619 developmental delay cases. We identified genes containing CNVs previously considered to be 
VOUS to be new candidate genes for neurodevelopmental disorders (GIT1, MVB12B and PPP1R9A) 
demonstrating the utility of this strategy to index the clinical effects of CNVs.
The broad umbrella classification of “developmental disorders” encompasses various conditions characterized 
by disturbance or delay of developmental milestones that appear in infancy or childhood. The cluster includes 
diagnostic entities that are themselves collectives, such as autism spectrum disorder (ASD), intellectual disability, 
learning disability, and others. The term may be used rather loosely, but is a common reason for referral to labora-
tories that offer genomic microarray for diagnostic evaluation. Developmental disorders affect ~3% of the popula-
tion, and reflect a significant genetic contribution1–3. In particular, large-scale genome-wide investigations3–9 have 
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demonstrated the large impact of copy number variation (CNV) on severe pediatric conditions, including various 
developmental disorders. As a result, whole genome “chromosomal microarray” (CMA) has come to be used as 
a first tier diagnostic test to elucidate causal CNVs in individuals with developmental disorders and congenital 
anomalies3,7,10. In a pediatric genetics laboratory, the variants detected by CMA are interpreted with respect to 
probable clinical significance, based on variant type (deletion or duplication), inheritance (de novo or present in a 
parent), gene content, gene density and evidence from published literature on association with diseases. For large, 
rare recurrent deletions and duplications (e.g., 16p11.2, 22q11.2, 15q13.2), the interpretation is rather obvious 
due to overwhelming genetic and phenotypic evidence. In a large multi-centre clinical data set, 15–20% of cases 
with developmental delay were associated with diagnostic findings on clinical chromosomal microarray3.
Among these diagnostic cases, many rare CNVs are detected for which the potential functional significance is 
unknown, and are referred to as variants of uncertain (or unknown) significance (VOUS). Variants deemed to be 
of clinical significance (or pathogenic) are fewer, and not all genes impacted by these variants will influence the 
developmental disability phenotype. Few candidate genes ascertained from clinically significant CNVs have been 
established as pathogenic through genetic studies; some are supported by model organism experiments6,11–15. The 
more abundant VOUS remain largely uncharacterized, and we need to investigate their expression and regulatory 
networks to understand their contribution to human cognition, behavior and disease. By virtue of the evaluation 
criteria, these variants are usually shorter than those classified as significant; they impact fewer exons or genes, 
and are mostly unique observations among cases studied3,7. A typical gene-level case-control association analysis 
of rare variants reveals thousands of genes to be apparently significant (Coe et al.6 reported ~3800 genes P < 0.01)6 
but these include many spurious signals that arise due to physical proximity to truly significant genes, given that 
large CNVs encompass multiple genes.
Genome-wide molecular data (transcriptomic, proteomic, etc.) facilitate inference of pathogenic mecha-
nisms through information about expression and regulatory networks and pathways at the molecular and cellular 
level16–19. Investigations of existing biological networks are biased towards the number of simplified interac-
tions20 or do not take tissue specificity into account21,22, yet these are important factors for the elucidation of 
phenotypically relevant genes23. The aim of this study was to assess the probable impact of variants in genes from 
within CNVs–both those established as clinically significant and VOUS–through knowledge of mutational bur-
den, and RNA and protein expression in various human brain tissues at different developmental stages (prenatal 
and adult). Previously, we developed a robust method, coupling information about the burden of exonic muta-
tions with exon-level expression, to quantify the critical nature of an exon in a given tissue at specified times in 
development (hence, spatio-temporal expression)24. We revealed an inverse correlation between exon expression 
level in brain and the burden of rare missense mutations found in population controls. Variants in these spe-
cific critical exons are significantly enriched among individuals with autism, relative to their unaffected siblings. 
Building upon this concept, we have now implemented an integrated genomics approach to analyze CMA data 
from DNA of individuals with developmental delay, to infer biologically relevant genes at the transcriptome 
and proteome levels. For this analysis, we added RNA-seq data from 388 postmortem brain tissues (prenatal to 
adult) and re-constructed the exon transcriptome contingency index for 226,845 exons from 19,631 genes. We 
identified ‘brain critical exons’ with i) a low burden (< 75th percentile for the genome) of rare (< 5%) missense 
and loss-of-function (LOF) mutations as identified from the 1,000 Genomes Project25, and ii) high expression 
(> 75th percentile for the genome) in brain tissue. We utilized these data to quantify the enrichment of ‘critical 
exons’ in 16 brain regions16. Next, we used genome-wide indexing of critical exons to quantify genes impacted by 
pathogenic or VOUS in developmental delay cases, and rare CNVs in controls. We used a comprehensive high 
resolution proteome dataset from prenatal and adult tissues (16) to analyze and extract biologically relevant gene 
co-expression networks. New candidate genes from within the pathogenic variants and VOUS were inferred from 
the aggregate analysis of spatio-temporal mRNA and protein expression data.
Results
Pathogenic variants and variants of uncertain significance. We analyzed 10,619 cases from two 
Ontario hospitals (The Hospital for Sick Children (SickKids) and Credit Valley Hospital (CVH)) referred for 
clinical laboratory testing due to developmental delay. We also used 9,692 controls (described in Methods) for 
whom no known psychiatric condition has been reported (Fig. 1 and Tables S1–S2). From this developmental 
delay cohort, 10.15% of the samples carried a pathogenic CNV, and 50.25% had at least one rare VOUS (Fig. 2A). 
In the SickKids subset (7,106 cases), which included inheritance information, there were 169 de novo variants 
(108 deletions and 61 duplications), of which 64% (108/169) were interpreted as pathogenic and 36% (61/169) as 
VOUS. To reduce platform specific sensitivity and specificity bias, we restricted our analysis to variants of 30 Kb 
to 5 Mb in length. The developmental delay cohort was 68.53% male and 31.46% female. There were pathogenic 
deletion variants in 5.26% of females and 3.69% of males, and this difference was highly significant (P < 0.0002) 
(Fig. 2B). This sex difference was not found for duplication CNVs (Fig. S1). The average number of genes with 
exonic variants differed significantly between pathogenic CNVs and VOUS. Genes per variant averaged 38 for 
pathogenic duplications, 27 for pathogenic deletions, 4.6 for VOUS duplications, and 3.2 for VOUS deletions 
(Fig. S2). The average number of genes in pathogenic deletions from females was higher than in those from males 
(Fig. S3). CNVs at loci for known genomic disorders26 were more frequent in our developmental delay cohort 
relative to controls, for example 16p11.2 (0.86%), 15q13.3 (0.43%), Prader-Willi syndrome (0.52%) and 22q11 
deletion/duplication syndrome (1.06%) (Fig. S4).
Critical Exon Analysis. Genes within pathogenic or VOUS CNVs in this developmental delay cohort had a 
significantly higher fraction of critical exons (computed over all exons impacted by CNVs), compared with genes 
in the rare duplications or deletions seen in controls (Table S2). Gene sets from pathogenic CNVs and VOUS were 
very large, and overlapped those from control CNVs; we limited the analysis to genes impacted by pathogenic 
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CNVs or VOUS from the case cohort, and not found in unaffected controls (Fig. 3). We observed a striking 
enrichment of critical exons (computed using prenatal brain transcriptome) within pathogenic deletions (cor-
rected Fisher’s Exact Test (FET) with P < 1.64 × 10−15 for a brain region) and VOUS deletions (P < 1.31 × 10−20 
to 6.22 × 10−158) (Fig. 3B). This result strongly suggests that pathogenic and VOUS variants harbor more critical 
exons than do the rare CNVs in controls. Although deletions showed the consistently highest sensitivity, we 
observed a similar increased critical exon fraction for pathogenic and VOUS duplications computed using prena-
tal and adult transcriptome (Fig. 3B and Fig. S5). We then used these exclusively pathogenic and VOUS gene sets 
to identify candidates for effects on developmental disorders. Of interest, the fraction of critical exons was highest 
in prenatal neocortical regions (specifically medial prefrontal cortex (MFC) tissues) for genes impacted by either 
pathogenic or VOUS deletions. This observation strongly supports previous independent reports of multiple 
neuropsychiatric patients with phenotypes associated with MFC27–29.
Protein co-expression analysis. Expression of mRNA is not highly correlated with protein expression, 
even within the same cells under similar conditions, due to many biological processes that impact mRNA prior to 
protein translation. Integrated analysis of transcriptome and proteome will provide more potent evidence of gene 
Figure 1. Schematic of the analysis framework to identify candidate genes from copy number variation 
in developmental delay, using genome-wide human (prenatal and adult) brain transcriptome (RNA 
sequencing) and proteome data (Fourier-transform mass spectrometry). The spatio-temporal transcriptome 
data was used to compute ‘brain critical exon’ analysis for all the genes in the genome. Quantified protein 
expression for each gene in the genome was used for weighted gene co-expression network analysis. To 
identify a candidate set of phenotypically relevant genes, integrated (transcriptome and proteome) analysis was 
conducted for genes impacted by rare CNVs in cases (pathogenic/VOUS) and controls. CVH, Credit Valley 
Hospital; VOUS, variant of unknown significance; DGV, Database of Genomic Variants.
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expression within a tissue. To examine the biological relevance of pathogenic and VOUS ‘critical exons’ at the pro-
tein level, we applied co-expression analysis using Fourier transformed protein expression data. We used a draft 
of the human proteome map (HPM) reported by Kim et al.19, obtained from mass spectrometry of 24 different 
human tissues (each pooled from 3 post-mortem samples) including 17 adult and 7 prenatal19. To our knowledge, 
ours is the most comprehensive human developmental (prenatal and adult) protein co-expression analysis using 
this high resolution Fourier transformed dataset. Unlike the biased seeding approach used to construct modules 
and networks30–32, we implemented an unbiased construction of networks, based on spatio-temporal protein 
expression, by applying a weighted gene co-expression network analysis (WGCNA)33. We applied WGCNA to 
Figure 2. Ascertainment of pathogenic variants or variants of uncertain significance (VOUS) in 10,619 
developmental delay cases. The rare CNVs of 30 kb to 5 Mb were classified as pathogenic variants or of VOUS. 
(A) Bars indicate the total number of CNVs in each classification. Of all samples assayed, 4.19% carried a 
pathogenic deletion, 1.81% a pathogenic duplication, 18.28% a VOUS deletion and 31.97% a VOUS duplication. 
The green line represents the number of unique genes impacted by the corresponding variants. (B) The 
percentage of male and female cases in the cohort impacted by pathogenic deletion variants. P value shown is 
for the one-sided Fisher’s exact test.
Figure 3. The fraction of critical exons (over all exons) computed from human prenatal brain regions 
for the genes impacted by pathogenic, VOUS and rare control deletion and duplication variants.  
(A,B) The critical exon fraction was computed using gene expression level quantified from RNA sequencing in 392 
brain tissues (controls) from 31 postmortem donors in 2 developmental periods (prenatal and adult) for 16 
brain regions (AMY, amygdaloid complex; CBC, cerebellar cortex; V1C, primary visual cortex; STC, posterior 
(caudal) superior temporal cortex; IPC, posterior inferior parietal cortex; A1C, primary auditory cortex; S1C, 
primary somatosensory cortex; M1C, primary motor cortex; STR, striatum; DFC, dorsolateral prefrontal 
cortex; MFC, medial prefrontal cortex; VFC, ventrolateral prefrontal cortex; OFC, orbital frontal cortex; MD, 
mediodorsal nucleus of thalamus; ITC, inferolateral temporal cortex; HIP, hippocampus). The critical exon 
fraction was computed using prenatal brain transcriptome for the genes impacted by pathogenic (red dots) or 
VOUS (orange dots) or rare control deletions (gray dots).
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the 17,294 genes represented by the proteome19 to construct protein co-expression networks. We excluded genes 
not expressed in at least 90% of the tissues. The analysis revealed networks for 23 independent protein expression 
modules (Fig. 4A). To identify modules that are relevant to developmental delay, we conducted gene enrichment 
analysis using 18,826 gene ontology (GO) terms, and retained the 20 most significant GO terms. From this analy-
sis, we identified the ‘blue’ module (Fig. 4A), which comprised 2,484 genes (Table S4), and was highly significant 
(P < 1.0 × 10−39 to 1.0 × 10−81) for pathways involved in synaptic transmission, neuron projection, cell signaling, 
nervous system development and axon guidance (Fig. 4B).
Identification of candidate developmental delay genes from integrated analysis. To develop 
a list of candidate genes related to developmental delay, we combined the two approaches - critical exon and 
WGCNA core protein–analyzing genes from the protein-derived ‘blue’ module for critical exon enrichment. 
For each gene in the genome, we computed the critical exons for prenatal and for adult tissues. To control for 
the genes with a large number of exons, for each gene in the genome, we computed the fraction of critical exons 
(over all exons) for a gene in each brain region. For each developmental period (prenatal or adult), a gene was 
deemed to be significant if its critical exon fraction fell within the genome’s top 25th percentile for at least 50% of 
the brain samples (Table S6). We found 48.5% (1,206/2,484) of ‘blue’ module proteins to be within the top 25th 
percentile of genes enriched for critical exons, both for prenatal (FET, P < 1.15 × 10−50, OR = 2.11) and adult 
brain (FET, P < 6.03 × 10−18, OR = 1.55) (Table S5). This included genes (SCN2A, NRXN1, NRXN2, NRXN3, 
SHANK2, NLGN3, STXBP1, NLGN4) known to be associated with neuropsychiatric conditions34,35. Inference 
of these 1,206 candidate genes, as described, was independent of the knowledge of gene-disease association. The 
overrepresentation of critical exon genes within the ‘blue’ module was tested by random permutation 100,000 
times to obtain an empirical significance (for both periods, P < 1.0 × 10−05) (Fig. 4C,D) using the appropriate 
background (please see methods).
Figure 4. Genome-wide protein co-expression and enrichment of genes ascertained from pathogenic 
and VOUS CNVs using human prenatal and adult tissues. (A) The protein modules generated by weighted 
gene coexpression network analysis (WGCNA) using high resolution genome-wide Fourier-transform mass 
spectrometry data from 30 histologically normal human samples (prenatal and adult). Each colour (bars 
dispersed) represents a module. (B) For the blue module, the 20 most significant results from quantitative 
association with 18,826 gene sets. (C) Representation of the ‘blue’ module as a functional network, where 
each node is a gene; the edge between genes represents the weighted Pearson distance. Red nodes represent 
genes ascertained through CNVs in the developmental delay cohort. (D) The top (25th percentile) critical exon 
genes in the genome ascertained using prenatal (green) and adult brain (purple) transcriptomes, and their 
corresponding quantified enrichment in the protein module, through Fisher’s exact test (FET) and 100,000 
permutations. The orange bar represents the original observation of overlaps between blue module and a gene 
set. Similarly, (E,F) show the enrichment of genes impacted by pathogenic and VOUS duplications (blue) and 
deletions (red) within the protein module.
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We then tested from within the ‘blue’ module for overrepresentation in tiers of genes that are associated with 
certain neurodevelopmental disorders. There was significant enrichment of the ‘blue’ module with 840 fragile 
X mental retardation protein (FMRP) target genes36 (P < 1.36 × 10−128, OR = 6.25; empirical P < 1.0 × 10−05), 
246 genes impacted with de novo LOF mutations in ASD cases35,37–40 (P < 5.9 × 10−04, OR = 1.79; empirical 
P < 2.1 × 10−04) and 141 genes that had de novo exonic deleterious mutations in intellectual disability samples41,42 
(P < 8.0 × 10−03; OR = 1.80; empirical P < 2.3 × 10−03) from exome and whole genome sequencing (Fig. S6A–C). 
This result suggested that proteins in this ‘blue’ module are under purifying selection in brain, and that perturbing 
them may lead to neurodevelopmental phenotypic manifestations.
Next, we looked for ‘blue’ module genes among those ascertained from CNVs in the developmental delay 
cohort. ‘Blue’ module genes were significantly overrepresented among genes within pathogenic deletions 
(P < 2.97 × 10−09; OR = 1.58; empirical P < 0.024) or duplications (P < 0.002; OR = 1.24; empirical P < 0.006) 
(1-sided FET and permutation test). They were similarly overrepresented among genes within VOUS deletions 
(P < 7.44 × 10–07; OR = 1.48; empirical P < 0.002) and duplications (P < 0.004; OR = 1.14; empirical P < 0.023) 
(Fig. 4E,F). In contrast, the genes within deletions and duplications in controls were not overrepresented within 
the ‘blue’ module. We found 438 candidate genes (of 1,206 genes) that were included in the ‘blue’ module and 
also highly enriched for critical exons (top 25th percentile), that had been ascertained by at least one pathogenic 
variant or VOUS in the developmental delay cohort (Table S5). Of these, 65 (14.84%) were seen in at least 2 VOUS 
deletions in cases but not controls. Another 37 of these 438 genes were impacted by at least one de novo VOUS 
in our dataset (Table S5). Genes from large recurrent CNVs known to be associated with neuropsychiatric syn-
dromes (e.g., 16p11.2, 22q11, and 3q29)43 were represented in the ‘blue’ protein module and were highly enriched 
for ‘critical exons’ in prenatal or adult brain (Table S6).
New candidate gene: GIT1. Through unbiased critical exon analysis coupled with WGCNA we identified 
1,206 candidate genes whose disruption is likely to contribute to neurodevelopmental delay (Table S5). For exam-
ple, in our cohort, VOUS deletions and duplications within chromosome region17q11.2 affect the gene for G 
protein-coupled receptor kinase interacting ArfGAP1 (GIT1). Within the VOUS in this region, GIT1 was the only 
gene enriched with critical exons in prenatal brain, and was highly clustered with genes (highly connected first 
degree neighbors) from within the ‘blue’ protein module network that were reported to have de novo mutations in 
ASD. The GIT1 protein is involved in cell migration44, localizes in pre- and post-synaptic terminals, and regulates 
synapse formation45. Recent studies of knock-out Git1− /− mice showed a decreased brain size, with impaired 
motor coordination and deficits in learning and memory46. From published data6 and on additional clinical 
cohorts (Mayo clinic, DatabasE of genomiC varIation and Phenotype in Humans using Ensembl Resources 
(DECIPHER) and Centre Hospitalier Universitaire Sainte-Justine clinic) we found enrichment of CNVs affecting 
GIT1 among cases (12 deletions and duplications, including 5 de novo; none in controls). The smallest focal dele-
tion of 180 kb was found in an 11-year-old child (Fig. 5A, Table S7 case 6D) referred for developmental delay, with 
epilepsy and attention deficit hyperactivity disorder as comorbid conditions. Another focal deletion was found as 
a de novo event of 299 kb in a 10-year-old child referred for developmental delay (case 1D-DN). The DECIPHER 
database showed a similar de novo focal 282 kb deletion affecting a child referred for learning disabilities, dys-
phasia and poor motor coordination (see phenotype Table S7 case 5D-DN). This source also identified two de 
novo duplications affecting GIT1: a 1.4 Mb de novo duplication in a patient referred for intellectual disability, and 
a focal 466 kb duplication in a patient with broader developmental delay. A de novo damaging missense mutation 
was also reported in a schizophrenia case47. We conducted quantitative real-time PCR (rt-PCR) analysis to quan-
tify relative mRNA expression (Supplementary text) of GIT1 on 11 human tissues (including prenatal and adult 
brain) by targeting a critical exon of the gene. GIT1 expression relative to that of the MED13 gene (or of the ACTB 
gene) showed brain specific expression in prenatal and adult tissue (Fig. 5C).
New candidate gene: MVB12B. We ascertained another candidate gene, multivesicular body subunit 
12B (MVB12B), with enrichment of critical exons, and also clustered with genes in the ‘blue’ network that were 
reported to be impacted by de novo exonic mutations in individuals with neuropsychiatric conditions. Initially 
we observed a single de novo duplication in our cohort, but subsequently found 18 VOUS involving this gene, 
including 12 that were de novo in origin (8 deletions and 4 duplications) (Fig. 6). This included 3 recurrent 
de novo CNVs ascertained from developmental delay cases impacting only the MVB12B gene (Fig. 6 and Table S7 
cases 6D-DN,4G-DN and 3G). The protein encoded by this gene is an endosomal sorting complex required for 
transport (ESCRT-I)48 which is involved in sorting of ubiquitinated cargo protein from the plasma membrane. 
Mutations in the ESCRT complex family have been implicated in frontotemporal dementia, a neurodegenera-
tive disease49. Our data included a de novo 839 kb duplication in a child (case 5G-DN) with Tourette syndrome, 
attention deficit hyperactivity disorder and learning disability. Another case had an adjacent de novo 700 kb dupli-
cation, and was described as having severe intellectual disability, whereas an individual (Fig. 6 case 3G) with a 
recurrent duplication was reported to be normal, thereby demonstrating variable expression (or reduced pene-
trance) of the duplication. Deletions were found in cases referred for developmental delay and reported to have 
other comorbid conditions (Table S7). The 73 kb smaller transcript of this gene (NM_001011703.2) containing 
the ‘critical exons’ in our analysis was impacted by 12 of our reported de novo VOUS and no CNVs in controls. 
Quantitative PCR analysis of 11 tissues for both MVB12B and PPP1R9A showed prenatal and adult brain-specific 
mRNA expression relative to that of the MED13 gene (or the ACTB gene).
New candidate gene: PPP1R9A. Our data set showed enrichment of deletion variants (4 VOUS, 
1 de novo) containing another gene from our candidate list: the protein phosphatase 1 regulatory subunit 9A 
(PPP1R9A) gene (Fig. S7). Additional data sets revealed 18 CNVs (13 deletions and 5 duplications), including 
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3 additional de novo deletions impacting exons of the gene. PPP1R9A is the only gene from within the de novo 
variants that is enriched with critical exons and clustered within the blue protein module (Fig. S7B). The nearby 
genes are impacted by polymorphic deletions in controls, whereas no deletions encompassing PPP1R9A were 
identified from the control data set. A de novo missense mutation of this gene was recently reported in an ASD 
proband40. This gene shows tissue-specific imprinting; it is maternally expressed in skeletal muscle, but both 
alleles are expressed in other embryonic tissues, including the brain50. The protein encoded by this gene, Neurabin 
I, is a key candidate molecule in synaptic formation and function50. PPP1R9A also has a role in synaptic struc-
ture and function, spine motility and neurite formation51. We observed enrichment of critical exons of this gene 
within adult brain regions (Fig. S7) and it is part of the ‘blue’ module. An individual with autism was found to 
have a de novo missense variant of PPP1R9A40 and a rare LOF mutation was reported in a schizophrenia case52. 
This gene also shows increased expression in brain from individuals with bipolar disorder compared with con-
trols53. Upon further investigation of the ‘blue’ protein co-expression network, highly connected neighboring 
(first degree) genes of PPP1R9A were reported to have de novo mutations in individuals with neuropsychiatric 
conditions32,35,37,42. In our cohort, a focal de novo 201 kb deletion affecting this gene was found in a child (Fig. S7 
and Table S7 case 11D-DN) referred for language delay, repetitive behaviors and sensory sensitivities, consistent 
with her diagnosis of ASD. A 2 Mb deletion impacting 15 genes–including PPP1R9A and the sarcoglycan epsilon 
(SGCE) gene - was found in a 12 year old girl (case 7D) referred for myoclonus dystonia, short stature, failure 
to thrive, severe anxiety and obsessive-compulsive behavior. She also had mild dysmorphic features (triangular 
facies, broad forehead, thin lips) but no cognitive concerns were reported.
Discussion
The brain transcriptome and proteomic method implemented here can infer candidate genes from within the 
boundaries of a pathogenic or VOUS CNV that are likely to impact brain-related conditions. Such lists of candi-
date genes can then be used to index the potential effect of a particular CNV or a set of CNVs in neurodevelop-
mental disorders.
The detection of genes critical for neurodevelopmental disorders is highly dependent on the breakpoints of the 
CNVs. Compared with sequencing technologies, clinical microarray tends to extend CNV breakpoints due to low 
probe density for the genome54. The low resolution impacts the precision of apparent breakpoints55, and CNVs 
may appear to encompass genes that may not be impacted by the real variant. Such false positives are reduced by 
large cohorts and high-resolution breakpoint detection through sequencing. Although HPM is one of the most 
Figure 5. Deletions within the GIT1 gene identified in developmental disorder cases or controls. (A) The 
breakpoints of 12 VOUS deletions (red) and duplications (blue) impacting GIT1 and nearby genes. The dataset 
includes 5 de novo deletions/duplications (denoted as DN) reported from developmental cases; no rare CNV 
was found in controls. (B) The analysis of the human protein co-expression network revealed that GIT1 is 
within the blue module and is highly connected (1-degree neighbors) with genes enriched for ‘critical exons’ 
(red nodes) and putative ASD genes reported to have de novo mutations (red node with black outline).  
(C) Expression of GIT1 (primer targeting critical exons) from quantitative real-time PCR (qRT-PCR) relative to 
housekeeping gene, MED13 (replicated with another housekeeping gene ACTB) in 11 different tissues.
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comprehensive protein expression datasets, it may not be perfect in the quantification of peptides across all tissues 
partly due to the peptide fractionation techniques. Further improvement on fractionation technique will provide 
more concrete protein expression profile of genes across different tissue types.
We have demonstrated a quantifiable approach to screen for genes that are candidates to be involved in neu-
rodevelopmental disorders, through the coordinated application of multiple genome-scale data sets. The critical 
exon approach reveals a negative selective pressure, whereas the protein expression analysis brings out networks 
that are in pathways biologically relevant to neurodevelopmental disorders31,56. This approach using CNVs 
could be augmented, through sequence analysis, to identify new genes, pathways and regulatory elements for 
a wide spectrum of neurodevelopmental phenotypes. Our recent work57,58 has shown that CNVs and smaller 
sequence-level variants (indels/single nucleotide variants (SNVs)) contribute - to autism spectrum disorder, and 
that whole genome sequencing, (which is capable of detecting both SNVs and CNVs) will become the ultimate 
standard for clinical genetic testing35,59. An approach such as ours that can assess the effects of mutations on genes 
in phenotypically relevant tissues will be important to reveal candidates for other classes of disorders. As large 
CNV and sequence level mutation datasets become available, large tissue specific RNA60 and protein expression 
dataset can be utilized for additional disease associations.
Through the approach described in this study, we have demonstrated the combined use of different types of 
molecular data from the human brain to interpret and identify candidate genes for developmental disorders, 
from pathogenic variants and VOUS. This quantifiable approach begins to enable the indexing of genes affected 
by CNVs for their potential role in neurodevelopmental disorders. Further functional characterization of these 
candidate genes and their products will allow us to define their regulation among tissues and throughout devel-
opment. This, in turn, may aid in steps for timely interventions to mitigate untoward effects of various genomic 
alterations.
Materials and Methods
Clinical microarray datasets. The clinical microarray (CMA) data were obtained from two independent 
sites: The Hospital for Sick Children (SickKids) (7.106 cases) and Credit Valley Hospital (CVH) (3.513 cases) 
from individuals referred for investigation of developmental delay (Table S1). In both sites, a International 
Figure 6. Deletions within MVB12B gene identified in developmental disorder cases and controls.  
(A) The breakpoints of 18 VOUS deletions (red) and duplications (blue) impacting MVB12B and nearby genes. 
The breakpoints include 12 de novo VOUS reported from developmental delay cases, including 3 recurrent 
breakpoints (6D-DN, 4G-DN, 3G). All de novo VOUS impacted the smaller isoform (highlighted by vertical 
dashed lines) of the gene (NM_001011703.2), and this was not impacted by CNV in controls. (B) The human 
protein co-expression network revealed that the MBV12B gene is the within the blue protein module and 
enriched for ‘critical exons’ (red nodes) and putative ASD genes reported to have de novo mutations (red node 
with black outline). (C) Expression of MVB12B (primer targeting critical exons) from quantitative real-time 
PCR (qRT-PCR) relative to housekeeping gene, MED13 (replicated with another housekeeping gene ACTB) in 
11 different tissues.
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Standards for Cytogenomic Arrays ISCA 180 K comparative genomic hybridization array (aCGH) was used to 
detect large CNVs by applying a circular binary segmentation algorithm61. For reference, we used a pool of 10 
samples to compare individual probe intensities. The clinical annotation for each sample variant was conducted 
by the clinical laboratory geneticist in each site.
Briefly, DNA from each case and pooled same-sex reference DNA (Promega, Madison, WI) were differentially 
labeled with Cy3-dCTP or Cy5-dCTP, respectively, and hybridized to the array slide according to the manufac-
turer’s protocol (Oxford Gene Technology). We scanned arrays using the Agilent G2505Bmicroarray scanner 
and analyzed data using the Agilent Feature Extraction software (10.7.11) and CytoSure Interpret Software ver-
sion 3.4.3 (OGT). Clinical interpretation of copy number variants was consistent with the American College of 
Genetics and Genomics guidelines62. When needed, we performed fluorescence in situ hybridization) analysis 
on cultured lymphocytes of parents, using standard protocols. Metaphase chromosomes were counter-stained 
with 4’,6-diamidino-2-phenylindole, and inverted grey scale imaging was used to visualize chromosome band-
ing patterns for chromosome identification, using the ISIS Metasytems imaging software version 5.5.4 (Newton, 
MA, USA). Deletions of less than 200 kb and duplications less than 700 kb were followed up by aCGH in parental 
samples.
As controls, we used data from 9,692 unrelated samples from individuals with no obvious psychiatric history, 
from multiple major population-scale studies that used high-resolution microarray platforms. These included 
4,347 control samples assayed by Illumina 1 M from the Study of Addiction Genetics and Environment (SAGE)63 
and the Health, Aging, and Body Composition (HABC)64; 2,988 control samples assayed by Illumina Omni 2.5 M 
from the Collaborative Genetic Study of Nicotine Dependence (COGEND)]65 and Cooperative Health Research 
in the Region of Augsburg KORA projects66; 2,357 control samples assayed by Affymetrix 6.0 from the Ottawa 
Heart Institute67 and the PopGen project68. In addition, we incorporated 11,255 control datasets assayed on 
Illumina platforms from ARIC and Wellcome Trust case control consortium (WTCCC2) projects6.
Critical exon classification. Burden of rare missense mutations. We used whole genome sequence data 
from the 1000 genomes project25 initiated by the US National Health Heart, Lung and Blood Institute (NHLBI) 
to calculate the burden of rare missense mutations in humans (495 males, and 544 females). Exonic regions had 
mean sequenced coverage of at least 20X. We used the RefSeq gene annotation model (which includes all exons 
from annotated isoforms) for our analysis. Genes with no variant calls were excluded. As described previously24, 
we annotated the variants using Annovar, and considered rare missense and LOF variants as strong proxies for 
recent (mostly within the last 5,000–10,000 years) rare deleterious mutation events in humans.
Spatio-temporal expression in human brain. We downloaded normalized RNA-seq data for spatio-temporal 
expression profiles of human brains from the BrainSpan database (http://www.brainspan.org/static/download.
html). We analyzed 388 tissue samples from 32 post-mortem brain donors (prenatal and adult). The expression 
measures for exons were provided as reads per kilobase per million (RPKM) from mapped reads. Method details 
for sequencing, alignment, quality control and expression quantification can be found in the BrainSpan Technical 
White Paper (http://www.brainspan.org/). We conducted our spatio-temporal (prenatal and adult) analysis on 
16 brain regions, including 11 neocortex regions (V1C, primary visual cortex; STC, posterior (caudal) superior 
temporal cortex; IPC, posterior inferior parietal cortex; A1C, primary auditory cortex; S1C, primary somatosen-
sory cortex; M1C, primary motor cortex; DFC, dorsolateral prefrontal cortex; MFC, medial prefrontal cortex; 
VFC, ventrolateral prefrontal cortex; OFC, orbital frontal cortex; ITC, inferolateral temporal cortex) and AMY, 
amygdaloid complex; CBC, cerebellar cortex; HIP, hippocampus; MD, mediodorsal nucleus of thalamus; and 
STR, striatum. We classified critical exons as described previously24.
Data from human protein expression at developmental stages. We used high-resolution 
genome-wide Fourier-transform mass spectrometry data (downloaded from the Human Proteome Map)19 to 
analyze protein expression levels in human tissues at two developmental stages. This included in-depth proteomic 
profiling of 30 histologically normal human samples, including 17 adult tissues (lung, heart, liver, gall bladder, 
adrenal gland, kidney, urinary bladder, prostate, testis, ovary, rectum, colon, pancreas, oesophagus, retina, fron-
tal cortex, and spinal cord) and 7 fetal tissues (liver, heart, brain, placenta, gut, ovary, testis)19. High-resolution 
Fourier transform mass spectrometers had been used for fragmentation (high-high mode) to process the data. 
This resulted in the identification of proteins encoded by 17,294 genes, accounting for approximately 84% of 
annotated protein-coding human genes19. We used average spectral counts per gene per sample as the measure 
for protein expression.
Weighted gene coexpression network analysis (WGCNA). We used the R WGCNA package69,70 to 
analyze the human protein expression. The use of weighted networks represents an improvement over unweighted 
networks because it preserves continuity of the co-expression information, and it is biologically robust with 
respect to parameter ß33. We excluded proteins that are rarely expressed (expression = 0 in at least 90% of the 
samples) because such low-expressed features tend to reflect noise, and correlations based on such counts are 
not really meaningful. We calculated the absolute value of the Pearson correlation coefficient for all pair-wise 
comparisons of protein expression values across all developmental tissue samples into a similarity matrix. We 
used blockwise network construction and a module detection method, where a block cluster consists of a max-
imum of 20,000 proteins. We constructed a signed adjacency matrix using a “soft” power adjacency function 
aij = |0.5 + 0.5 * cor(xi, xj)|β , where the absolute value of the Pearson correlation measures protein co-expression 
similarity, and aij represents the resulting adjacency–reflecting the connection strength. We chose for our analysis 
the soft threshold beta = 18, based on the scale-free topology33 criterion ß (63). Next, to compute modules, where 
the proteins have high “topological overlap”, we compared connection strength between proteins in the network. 
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The parameters for module detection were: minimum 30 proteins per module and a medium sensitivity deep-
split = 2 was applied to cluster splitting. The clustering of genes for modules used average linkage hierarchical 
clustering; modules were identified in the resulting dendrogram by the dynamic hybrid tree cut. Such modules 
were trimmed of genes whose correlation with module eigengene (KME) was less than a threshold defined by 
the function minKMEtoStay; for merging similar modules, we used 0.35 as a threshold. The connectivity of each 
node i is the sum of connections to other nodes.
For visualizing the protein co-expression network, we used Cytoscape network software v.2.8.3. A node is 
represented by a circle, and the edge represented by a line between the nodes implies the co-expression weighted 
Pearson distance. The color of the node represents membership to a phenotype.
Significant test analysis and permutation test. We used Fisher’s exact test (FET) for all count data 
and g p-value < 0.05 (after Bonferroni multiple test correction) as the threshold for significance in tests of gene 
enrichment. To reveal the strength of enrichment association with the gene lists, we undertook a permutation test 
by randomly drawing equal numbers of genes and re-analyzing the data under the null-hypothesis. The random 
draw was conducted from a background appropriate for the test. To analyze enrichment of critical exon genes 
(top 25th percentile) within the ‘blue’ protein module (Fig. 4D), the background included all genes for which we 
had both protein expression and mRNA expression from RNA-seq data. For the analysis of pathogenic and VOUS 
deletion/duplication gene enrichment within the ‘blue’ protein module, we used all genes with protein expres-
sion as the background. In each iteration of the random draw, an equal (to the original set) number of genes was 
drawn. With sufficient iterations (100,000 times), the resulting sets of p-values are presumed to be a reasonable 
approximation of the null distribution of the p-values.
Reverse transcription polymerase chain reaction (RT-PCR) and quantitative RT-PCR 
(qRT-PCR). To quantitate ‘critical exons’ by qRT-PCR, primers were designed to prime from within the spe-
cific exon (Supplementary Table S8). We tested PCR efficiency with a dilution standard curve, and for specific-
ity with melting curve analysis using adult whole brain cDNA. To quantify the ‘critical exon’ expression from 
selected genes, we used RNA from a panel of 11 human tissues: liver (BD Biosciences), kidney (Stratagene), 
mammary gland (BD Biosciences), cerebellum (Clonetech), skeletal muscle (Stratagene), prostate (Clonetech), 
spleen (Stratagene), thyroid (Stratagene) and testis (Clonetech). Reverse transcription was performed using the 
Superscript III First strand Synthesis Supermix (Invitrogen). We used 10 ng of cDNA as template for RT-PCR 
under standard PCR conditions, using Brilliant III SYBR® Green PCR Master Mix (Agilent) and the MX300 
software (Agilent). Gene expression was normalized using MED13 or ACTB (dCt) and quantified as relative 
expression (2^(-dCt)).
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